Roth Capital Downgrades Exact Sciences (EXAS) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Jefferies Cuts Price Target on Exact Sciences (EXAS) Following Disappointing Outlook
February 25, 2016 9:29 AM ESTJefferies maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $13.00 (from $15.00), following the company's 4Q. . In light of the 4Q test volume shortfall, EXAS' initial outlook for flattish trends in 1Q16 was disappointing. EXAS reaffirmed its '16 revenue... More
Stephens Downgrades Exact Sciences (EXAS) to Equal Weight
February 25, 2016 7:55 AM ESTStephens downgraded Exact Sciences (NASDAQ: EXAS) from Overweight to Equal Weight.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $5.87 yesterday.
... MoreCraig-Hallum Downgrades Exact Sciences (EXAS) to Hold
February 24, 2016 1:37 PM ESTCraig-Hallum downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Hold.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $6.41 yesterday.
... MoreExact Sciences (EXAS) Tops Q4 EPS by 6c, Maintains Cologuard Outlook
February 24, 2016 7:31 AM ESTExact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.41), $0.06 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $14.82 million.
2016 Outlook
The company continues to anticipate completing more than 240,000 Cologuard tests during 2016, generating between... More
